D Walmrath, T Schneider, J Pilch, R Schermuly, F Grimminger and W Seeger
Department of Internal Medicine, Justus-Liebig University Giessen, Germany.

The effects of aerosolized prostaglandin (PG) I2 on gas exchange and hemodynamics were investigated in patients ventilated mechanically because of severe community-acquired pneumonia. Group A were patients without preexisting lung disease (n = 6), and Group B were those with underlying chronic fibrotic interstitial lung disease (n = 6). Ventilation-perfusion distribution was assessed by the multiple inert gas elimination technique. In Group A, low doses of aerosolized PGI2 (mean, 6.6 +/- 3.0 ng/kg/min) sufficed to decrease the mean pulmonary artery pressure (Ppa) from 35.0 +/- 1.5 to 31.0 +/- 1.6 mm Hg (p < 0.05), to improve the ratio of arterial oxygen to the fraction of inspired oxygen (PaO2/FIO2 increase from 100 +/- 18 to 134 +/- 18; p < 0.05), and to decrease intrapulmonary shunt (36.9 +/- 4.7 to 27.5 +/- 4.5%; p < 0.05). Systemic arterial pressure (Psa) and cardiac output remained unchanged. In Group B, aerosolized PGI2 was ineffective in doses less than 10 ng/kg/min. A dosage of 33.6 +/- 12 ng/kg/min reduced Ppa (38.0 +/- 2.4 to 30.8 +/- 2.1 mm Hg; p < 0.05), but it also decreased Psa (80.3 +/- 3.6 to 71.3 +/- 4.7 mm Hg; NS) and PaO2/FIO2 (73.8 +/- 6.6 to 65.5 +/- 6.8 mm Hg; p < 0.05) values and increased intrapulmonary shunt (44.7 +/- 3.0 to 49.4 +/- 5.0%, NS). After withdrawal of the PGI2 aerosol, all gas exchange and hemodynamic changes returned to preaerosol baseline values within 60 min in both groups.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, S. Nikkho, R. Speich, M. M. Hoeper, J. Behr, et al. Inhaled Iloprost for Severe Pulmonary Hypertension N. Engl. J. Med., August 1, 2002; 347(5): 322 - 329. [Abstract] [Full Text] [PDF]

				M. Beghetti, G. Reber, P. de Moerloose, L. Vadas, A. Chiappe, I. Spahr-Schopfer, and P.C. Rimensberger Aerosolized iloprost induces a mild but sustained inhibition of platelet aggregation Eur. Respir. J., March 1, 2002; 19(3): 518 - 524. [Abstract] [Full Text] [PDF]

				M. Hache, A. Y. Denault, S. Belisle, P. Couture, D. Babin, F. Tetrault, and J.-G. Guimond Inhaled prostacyclin (PGI2) is an effective addition to the treatment of pulmonary hypertension and hypoxia in the operating room and intensive care unit : [L'inhalation de prostacycline (PGI2) est un traitement complementaire efficace de l'hypertension pulmonaire et de l'hypoxie observees en salle d'operation et a l'unite des soins intensifs] Can J Anesth, October 1, 2001; 48(9): 924 - 929. [Abstract] [Full Text] [PDF]

				N. Nagaya, C. Yokoyama, S. Kyotani, M. Shimonishi, R. Morishita, M. Uematsu, T. Nishikimi, N. Nakanishi, T. Ogihara, M. Yamagishi, et al. Gene Transfer of Human Prostacyclin Synthase Ameliorates Monocrotaline-Induced Pulmonary Hypertension in Rats Circulation, October 17, 2000; 102(16): 2005 - 2010. [Abstract] [Full Text] [PDF]

				H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group* Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial Ann Intern Med, March 21, 2000; 132(6): 435 - 443. [Abstract] [Full Text] [PDF]

				P. V. van Heerden, A. Barden, N. Michalopoulos, M. K. Bulsara, and B. L. Roberts Dose-Response to Inhaled Aerosolized Prostacyclin for Hypoxemia Due to ARDS Chest, March 1, 2000; 117(3): 819 - 827. [Abstract] [Full Text] [PDF]

				R. T. Schermuly, A. Roehl, N. Weissmann, H. A. Ghofrani, C. Schudt, H. Tenor, F. Grimminger, W. Seeger, and D. Walmrath Subthreshold Doses of Specific Phosphodiesterase Type 3 and 4 Inhibitors Enhance the Pulmonary Vasodilatory Response to Nebulized Prostacyclin with Improvement in Gas Exchange J. Pharmacol. Exp. Ther., February 1, 2000; 292(2): 512 - 520. [Abstract] [Full Text]

				A. GÜNTHER, P. MOSAVI, S. HEINEMANN, C. RUPPERT, H. MUTH, P. MARKART, F. GRIMMINGER, D. WALMRATH, B. TEMMESFELD-WOLLBRÜCK, and W. SEEGER Alveolar Fibrin Formation Caused by Enhanced Procoagulant and Depressed Fibrinolytic Capacities in Severe Pneumonia . Comparison with the Acute Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 454 - 462. [Abstract] [Full Text]

				R. T. SCHERMULY, H. A. GHOFRANI, B. ENKE, N. WEISSMANN, F. GRIMMINGER, W. SEEGER, C. SCHUDT, and D. WALMRATH Low-dose Systemic Phosphodiesterase Inhibitors Amplify the Pulmonary Vasodilatory Response to Inhaled Prostacyclin in Experimental Pulmonary Hypertension Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1500 - 1506. [Abstract] [Full Text]

				H. OLSCHEWSKI, H. ARDESCHIR GHOFRANI, D. WALMRATH, R. SCHERMULY, B. TEMMESFELD-WOLLBRÜCK, F. GRIMMINGER, and W. SEEGER Inhaled Prostacyclin and Iloprost in Severe Pulmonary Hypertension Secondary to Lung Fibrosis Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 600 - 607. [Abstract] [Full Text]

				C. PUTENSEN, C. HORMANN, A. KLEINSASSER, and G. PUTENSEN-HIMMER Cardiopulmonary Effects of Aerosolized Prostaglandin E1 and Nitric Oxide Inhalation in Patients with Acute Respiratory Distress Syndrome Am. J. Respir. Crit. Care Med., June 1, 1998; 157(6): 1743 - 1747. [Abstract] [Full Text] [PDF]

				H. Schütte, F. Grimminger, J. Otterbein, R. Spriestersbach, K. Mayer, D. Walmrath, and W. Seeger Efficiency of Aerosolized Nitric Oxide Donor Drugs to Achieve Sustained Pulmonary Vasodilation J. Pharmacol. Exp. Ther., August 1, 1997; 282(2): 985 - 994. [Abstract] [Full Text]

				D. Royston Surgery with cardiopulmonary bypass and pulmonary inflammatory responses Perfusion, May 1, 1996; 11(3): 213 - 219. [PDF]